IGF-I and IGFBP-3 and the risk of lung cancer: A meta-analysis based on nested case-control studies

Bo Chen,Shan Liu,Wei Xu,Weihong Zhao,Jianqing Wu,Xueli Wang

doi:10.1186/1756-9966-28-89

Bo Chen, Shan Liu + Show 4 more

Open Access

https://doi.org/10.1186/1756-9966-28-89

Copy DOI

Abstract

BackgroundLung cancer is the leading cause of death from cancer worldwide. Conventional studies mainly think that insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) may promote and inhibit tumor growth, respectively. However, there are many different results about their function in some recent epidemiological studies. To evaluate the relationship between circulating serum levels of IGF-I, IGFBP-3 and lung cancer, a systematic review and meta-analysis of the published data was performed.MethodsLiteratures searched on PubMed and Embase databases were enrolled in the Meta-analysis. The Meta-analysis of all eligible studies was applied with Stata 10.0 software, and the pooled odds ratio(OR) and weighted mean difference (WMD) value were obtained. The Q test, Egger's test and Begg's funnel plot were used to evaluate the heterogeneity and publication bias between the studies.ResultsThere are no statistically significant heterogeneity and publication bias between the studies. For IGF- I, the pooled OR and WMD were 0.87(95%CI: 0.60~1.13,) and -3.04(95%CI: -7.10~1.02, P = 0.14), respectively. For IGFBP-3, the pooled OR and WMD were 0.68(95%CI: 0.48~0.88,) and -112.28(95%CI: -165.88~-58.68, P < 0.0001), respectively.ConclusionThe association between circulating IGF- I levels and the risk of lung cancer were not statistically significant; IGFBP-3, acts as a tumor suppressor and has a inverse correlation with the risk of lung cancer.

Highlights

Lung cancer is the leading cause of death from cancer worldwide
insulin-like growth factor-I (IGF-I) is released locally in response to damage, either directly or through the action of other factors associated with tissue responses to damage, including epidermal growth factor, fibroblast growth factor, and platelet-derived growth factor [8]
Search strategy and study selection PubMed and Embase were searched using the search terms: "insulin-like growth factor-I", "lung neoplasm", "case-control study", "cohort study" and "prospective study"

Summary

Introduction

Lung cancer is the leading cause of death from cancer worldwide. Conventional studies mainly think that insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) may promote and inhibit tumor growth, respectively. To evaluate the relationship between circulating serum levels of IGF-I, IGFBP-3 and lung cancer, a systematic review and meta-analysis of the published data was performed. Lung cancer is the leading cause of death from cancer worldwide, and the care rate remains less than 15% despite improvements in surgery, radiotherapy and chemotherapy [1]. Insulin-like growth factor-I (IGF-I) and IGFbinding protein-3 (IGFBP-3) have been widely accepted that they may have key role on the genesis and development of many types of tumor including lung cancer [2,3,4,5,6,7].

Methods

Results

Conclusion